{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:34:57Z","timestamp":1792301697824,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s11883-019-0794-6","type":"journal-article","created":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T08:02:32Z","timestamp":1561190552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease"],"prefix":"10.1007","volume":"21","author":[{"given":"Sehrish","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar D.","family":"Navaneethan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,22]]},"reference":[{"key":"794_CR1","unstructured":"United States Renal Data System. 2018 USRDS annual data report: epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2018."},{"issue":"10","key":"794_CR2","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1681\/ASN.2014101034","volume":"26","author":"SD Navaneethan","year":"2015","unstructured":"Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV Jr. Cause-specific deaths in non-dialysis-dependent CKD. J Am Soc Nephrol. 2015;26(10):2512\u201320.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"794_CR3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2017.12.007","volume":"72","author":"LP Gregg","year":"2018","unstructured":"Gregg LP, Hedayati SS. Management of traditional cardiovascular risk factors in CKD: what are the data? Am J Kidney Dis. 2018;72(5):728\u201344.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"794_CR4","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jacc.2010.02.068","volume":"56","author":"MJ Jardine","year":"2010","unstructured":"Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56(12):956\u201365. https:\/\/doi.org\/10.1016\/j.jacc.2010.02.068 .","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"794_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2337\/dc10-1615","volume":"34","author":"Y Saito","year":"2011","unstructured":"Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, et al. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care. 2011;34(2):280\u20135.","journal-title":"Diabetes Care"},{"key":"794_CR6","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016;134(10):e123\u201355."},{"issue":"16","key":"794_CR7","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706\u201317.","journal-title":"N Engl J Med"},{"key":"794_CR8","doi-asserted-by":"crossref","unstructured":"\u2022 Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2013(2):CD008834. This systematic review examined the effects of various platelet agents in those with CKD. Data from primary and secondary prevention has been presented separately.","DOI":"10.1002\/14651858.CD008834.pub2"},{"issue":"6","key":"794_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.7326\/0003-4819-156-6-201203200-00007","volume":"156","author":"SC Palmer","year":"2012","unstructured":"Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;156(6):445\u201359.","journal-title":"Ann Intern Med"},{"issue":"5","key":"794_CR10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67(5):728\u201341.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"794_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","volume":"157","author":"SC Palmer","year":"2012","unstructured":"Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):263\u201375.","journal-title":"Ann Intern Med"},{"key":"794_CR12","unstructured":"Group KCW. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2012;1\u2013150."},{"issue":"4","key":"794_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","volume":"155","author":"PJ Best","year":"2008","unstructured":"Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155(4):687\u201393.","journal-title":"Am Heart J"},{"issue":"9784","key":"794_CR14","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"F Prof Colin Baigent","year":"2011","unstructured":"\u2022\u2022 Prof Colin Baigent F, Martin J Landray F, Christina Reith M, Jonathan Emberson P, David C Wheeler F, Charles Tomson D, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392 This the largest clinical trial which demonstrated the cardiovascular benefits of statins plus ezetimibe in those with different stages of chronic kidney disease.","journal-title":"Lancet"},{"issue":"10","key":"794_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","volume":"4","author":"C Cholesterol Treatment Trialists","year":"2016","unstructured":"Cholesterol Treatment Trialists C, Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4(10):829\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"794_CR16","unstructured":"KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013:259\u2013305."},{"key":"794_CR17","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary 0(0):CIR.0000000000000624."},{"issue":"16","key":"794_CR18","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399.","journal-title":"N Engl J Med"},{"issue":"18","key":"794_CR19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"6","key":"794_CR20","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","volume":"169","author":"DJ Kereiakes","year":"2015","unstructured":"Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, et al. Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906\u201315 e13.","journal-title":"Am Heart J"},{"issue":"19","key":"794_CR21","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","volume":"36","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186\u201394.","journal-title":"Eur Heart J"},{"issue":"6","key":"794_CR22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.kint.2018.01.030","volume":"93","author":"M Mafham","year":"2018","unstructured":"Mafham M, Haynes R. PCSK9 inhibition: ready for prime time in CKD? Kidney Int. 2018;93(6):1267\u20139.","journal-title":"Kidney Int"},{"issue":"9731","key":"794_CR23","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073\u201381.","journal-title":"Lancet"},{"issue":"22","key":"794_CR24","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103\u201316.","journal-title":"N Engl J Med"},{"issue":"17","key":"794_CR25","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575\u201385.","journal-title":"N Engl J Med"},{"issue":"9","key":"794_CR26","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1681\/ASN.2017020148","volume":"28","author":"AK Cheung","year":"2017","unstructured":"\u2022\u2022 Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017;28(9):2812\u201323 This study reported the cardiovascular benefits of intensive blood pressure control in those with non-dialysis-dependent CKD.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"794_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.7326\/M16-2966","volume":"167","author":"S Beddhu","year":"2017","unstructured":"Beddhu S, Rocco MV, Toto R, Craven TE, Greene T, Bhatt U, et al. Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial. Ann Intern Med. 2017;167(6):375\u201383.","journal-title":"Ann Intern Med"},{"issue":"5","key":"794_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507\u201320.","journal-title":"JAMA"},{"issue":"6","key":"794_CR29","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71(6):1269\u2013324.","journal-title":"Hypertension"},{"key":"794_CR30","unstructured":"Group KC. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012:337\u2013414."},{"issue":"3","key":"794_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"794_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"794_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","volume":"134","author":"JF Mann","year":"2001","unstructured":"Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629\u201336.","journal-title":"Ann Intern Med"},{"issue":"10","key":"794_CR34","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","volume":"123","author":"SW Tobe","year":"2011","unstructured":"Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011;123(10):1098\u2013107.","journal-title":"Circulation"},{"issue":"20","key":"794_CR35","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892\u2013903.","journal-title":"N Engl J Med"},{"issue":"6","key":"794_CR36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2215\/CJN.07800811","volume":"7","author":"M Rahman","year":"2012","unstructured":"Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, et al. Long-term renal and cardiovascular outcomes in antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol. 2012;7(6):989\u20131002.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"794_CR37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/hr.2009.44","volume":"32","author":"T Saruta","year":"2009","unstructured":"Saruta T, Hayashi K, Ogihara T, Nakao K, Fukui T, Fukiyama K, et al. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J study. Hypertens Res. 2009;32(6):505\u201312.","journal-title":"Hypertens Res"},{"key":"794_CR38","first-page":"347","volume":"f5680","author":"T Ninomiya","year":"2013","unstructured":"Blood Pressure Lowering Treatment Trialists C, Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ. 2013;f5680:347.","journal-title":"BMJ"},{"key":"794_CR39","doi-asserted-by":"crossref","unstructured":"ADVANCE collaborative group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560\u201372.","DOI":"10.1056\/NEJMoa0802987"},{"issue":"5","key":"794_CR40","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","volume":"60","author":"National Kidney F","year":"2012","unstructured":"National Kidney F. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850\u201386.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"794_CR41","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"794_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"\u2022\u2022 Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334 Data from large clinical trial demonstrating benefits of SGLT2 inhibitors on renal outcomes.","journal-title":"N Engl J Med"},{"issue":"3","key":"794_CR43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/ndt\/gfw452","volume":"32","author":"J Xia","year":"2017","unstructured":"Xia J, Wang L, Ma Z, Zhong L, Wang Y, Gao Y, et al. Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol Dial Transplant. 2017;32(3):475\u201387.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"794_CR44","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1053\/j.ajkd.2016.02.052","volume":"68","author":"N Staplin","year":"2016","unstructured":"Staplin N, Haynes R, Herrington WG, Reith C, Cass A, Fellstrom B, et al. Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP). Am J Kidney Dis. 2016;68(3):371\u201380.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"794_CR45","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1053\/j.ajkd.2014.09.016","volume":"65","author":"AC Ricardo","year":"2015","unstructured":"Ricardo AC, Anderson CA, Yang W, Zhang X, Fischer MJ, Dember LM, et al. Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis. 2015;65(3):412\u201324.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"794_CR46","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2337\/diacare.17.2.126","volume":"17","author":"PT Sawicki","year":"1994","unstructured":"Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 1994;17(2):126\u201331.","journal-title":"Diabetes Care"},{"issue":"6","key":"794_CR47","first-page":"337","volume":"14","author":"G Gambaro","year":"2001","unstructured":"Gambaro G, Bax G, Fusaro M, Normanno M, Manani SM, Zanella M, et al. Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. Diabetes Nutr Metab. 2001;14(6):337\u201342.","journal-title":"Diabetes Nutr Metab"},{"issue":"2","key":"794_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00000441-200402000-00001","volume":"327","author":"T Chuahirun","year":"2004","unstructured":"Chuahirun T, Simoni J, Hudson C, Seipel T, Khanna A, Harrist RB, et al. Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Med Sci. 2004;327(2):57\u201367.","journal-title":"Am J Med Sci"},{"issue":"7","key":"794_CR49","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481\u20136.","journal-title":"Diabetes Care"},{"key":"794_CR50","doi-asserted-by":"publisher","first-page":"k5301","DOI":"10.1136\/bmj.k5301","volume":"364","author":"AR Chang","year":"2019","unstructured":"Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2019;364:k5301.","journal-title":"BMJ."},{"issue":"1","key":"794_CR51","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1681\/ASN.2017010020","volume":"29","author":"TA Ikizler","year":"2018","unstructured":"\u2022 Ikizler TA, Robinson-Cohen C, Ellis C, Headley SAE, Tuttle K, Wood RJ, et al. Metabolic effects of diet and exercise in patients with moderate to severe CKD: a randomized clinical trial. J Am Soc Nephrol. 2018;29(1):250\u20139 This clinical trial demonstrated the feasibility of diet and exercise interventions in those with chronic kidney disease.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"794_CR52","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S2213-8587(14)70156-1","volume":"2","author":"ARG Look","year":"2014","unstructured":"Look ARG. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2(10):801\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"794_CR53","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1161\/CIRCULATIONAHA.118.038341","volume":"139","author":"BM Scirica","year":"2019","unstructured":"Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, et al. Lorcaserin and renal outcomes in obese and overweight patients in the CAMELLIA-TIMI 61 trial. Circulation. 2019;139(3):366\u201375.","journal-title":"Circulation"},{"issue":"3","key":"794_CR54","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1161\/CIRCULATIONAHA.118.038677","volume":"139","author":"SD Navaneethan","year":"2019","unstructured":"Navaneethan SD. Trials and tribulations in studying kidney outcomes with intentional weight loss. Circulation. 2019;139(3):376\u20139.","journal-title":"Circulation"},{"key":"794_CR55","unstructured":"Global Recommendations on Physical Activity for Health. WHO Guidelines Approved by the Guidelines Review Committee. Geneva; 2010."},{"key":"794_CR56","unstructured":"Physical Activity Guidelines Advisory Committee report, 2008. To the Secretary of Health and Human Services. Part a: executive summary. Nutr Rev. 2009;67(2):114\u201320."},{"issue":"19","key":"794_CR57","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1161\/CIRCULATIONAHA.107.729939","volume":"116","author":"S Mora","year":"2007","unstructured":"Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation. 2007;116(19):2110\u20138.","journal-title":"Circulation"},{"issue":"3","key":"794_CR58","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1053\/j.ajkd.2014.03.020","volume":"64","author":"S Heiwe","year":"2014","unstructured":"Heiwe S, Jacobson SH. Exercise training in adults with CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2014;64(3):383\u201393.","journal-title":"Am J Kidney Dis"},{"key":"794_CR59","doi-asserted-by":"publisher","unstructured":"WRITING COMMITTEE MEMBERS, Arnett DK, Blumenthal RS, Albert MA, Michos ED, Buroker AB, Miedema MD, Goldberger ZD, Mu\u00f1oz D, Hahn EJ, Smith Jr SC, Himmelfarb CD, Virani SS, Khera A, Williams Sr KA, Lloyd-Jones D, Yeboah J, McEvoy JW, Ziaeian B, ACC\/ AHA TASK FORCE MEMBERS, O\u2019Gara PT, Beckman JA, Levine GN, Chair IP, Al-Khatib SM, Hlatky MA, Birtcher KK, Ikonomidis J, Cigarroa JE, Joglar JA, Deswal A, Mauri L, Fleisher LA, Piano MR, Gentile F, Riegel B, Goldberger ZD, Wijeysundera DN. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease. J Am Coll Cardiol. 2019. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.010 .","DOI":"10.1016\/j.jacc.2019.03.010"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-019-0794-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-019-0794-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-019-0794-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T15:42:11Z","timestamp":1663774931000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-019-0794-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,22]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["794"],"URL":"https:\/\/doi.org\/10.1007\/s11883-019-0794-6","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,22]]},"assertion":[{"value":"22 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors report no relevant financial interest in the contents of this review. Outside the submitted work, S.D.N. has served on the event adjudication committee for clinical trials sponsored by Bayer and Boehringer Ingelheim, served as a consultant for Tricida, and has received investigator-initiated research support from Keryx Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"32"}}